The Biotech Therapy for Atypical Patients by Clay Siegall

Dr, Clay Siegall is the founder, chairman, president and CEO of Seattle Genetics. Seattle Genetics was established in 1998 to address the unexplored medical field of antibody therapy for cancer and rare diseases. The company has grown regarding facilities, application, and staff capacity. Seattle Genetics was the first pioneer company to be approved by FDA for antibody drug manufacture commercially.

Apparently, they have been able to produce over 20 drugs in collaboration with drug manufacturers and pharmaceutical companies such as Takeda Pharmaceuticals, Bayer, Pfizer and Genentech just to mention a few. This has harmonized a team of specialized medical researchers working day and night to come up with new and better innovations in drug development and cancer treatment. Seattle Genetics now has a wide portfolio of antibody-based drugs.

Dr. Clay Siegall developed interest first in cancer treatment when his relative almost succumbed to it, not for cancer but rather the chemotherapy procedure. Motivated by technological advancement, he began researching for alternative modes of target therapy and not the systematic chemotherapies. In his fact-finding effort at the school identified radical surgery and amputation as an alternative treatment. Driven by this, Seattle Genetics came to being.

The company has become very relevant in the 21st century that has been characterized by a high rise in the number of patients with rare and fatal diseases. In the process, the company makes profits from the sale of FDA approved antibody drug, production partnership and licensing of technologies. From the portfolio, ADCetris is doing well and was recently approved for three indications. The company has over $675 million through public and private financing, which is a good amount.

About Dr. Clay Siegall

Siegall holds a Bachelor of Science from the University of Maryland and a Ph.D. in Genetics from George Washington. He has authored more than 70 publications and 15 patents. Clay Siegall has in the past worked for the Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. He has been affiliated with various institutions by the virtue of being a board member. Such institutions include Alder BioPharmaceuticals, Washington Roundtable, Mirna Therapeutics and Ultragenyx Pharmaceuticals.

 

Gary